ANDA 90125, held by Navinta. Nicardipine Hydrochloride.
As of Nov 22, 2026, ANDA 90125 (Nicardipine Hydrochloride), held by Navinta, was first approved by FDA on Nov 17, 2009, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nicardipine Hydrochloride25MG/10ML (2.5MG/ML) · injectable;injection | Nicardipine Hydrochloride | Discontinued |
| Apr 29, 2011 | Supplement 1Labeling | Approved | None posted |
| Nov 17, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters